Tocilizumab
Trial supports tocilizumab in moderate-to-severe COVID-19-associated pneumonia
A follow-up analysis of the CORIMUNO-TOCI-1 randomized clinical trial showed that tocilizumab may be considered for treating patients with moderate-to-severe COVID-19-associated pneumonia and high C-reactive protein levels.
Tocilizumab holds firm as steroid-sparing agent in giant cell arteritis
Tocilizumab, the one biologic therapy that has FDA approval for giant cell arteritis, has shown ongoing efficacy in keeping patients in remission and off steroids, according to a pair of presenters at the Biologic Therapies Summit.
CAR T-cell therapy, bispecific T-cell engagers, other exciting treatments in multiple myeloma
Maung Myo Htut, MD, associate clinical professor in the division of multiple myeloma within the department of hematology and hematopietic cell transplantation at City of Hope, discussed treatment developments in multiple myeloma, including exciting data from ASH 2020, the role of CAR T-cell therapy, autologous hematopoietic stem cell transplant, consolidation therapy and more.
Novel therapies, combinations show 'increasing evidence' for role in SSc-ILD
A number of new therapies, including immunosuppressive drugs and drug combinations, have shown efficacy in mitigating scleroderma-associated interstitial lung disease, according to a speaker at the ACR State-of-the-Art Clinical Symposium.
'Fire hydrant' of COVID-19 data tasks clinicians with conflicting evidence, mixed results
Given the global deluge of data investigating COVID-19 in patients with rheumatic and immune-mediated diseases, clinicians continue to struggle with divergent evidence and recommendations, noted a speaker at the ACR State-of-the-Art Clinical Symposium.
Tocilizumab improves GCA outcomes in patients with polymyalgia, cranial symptoms
Tocilizumab improves outcomes in patients with giant cell arteritis who present with polymyalgia rheumatica symptoms only, cranial symptoms only or both at baseline, according to data published in Seminars in Arthritis & Rheumatism.
GiACTA: Giant cell arteritis remission maintained in 42% of patients after drug cessation
A substantial proportion of patients who received tocilizumab for giant cell arteritis for 1 year remain in drug-free remission throughout the 2 years after ceasing therapy, according to data published in The Lancet Rheumatology.
IDSA updates treatment guidance for COVID-19, including monoclonal antibodies
The Infectious Diseases Society of America has updated its treatment guidelines for COVID-19 for several therapies, including tocilizumab, ivermectin and bamlanivimab with etesevimab.
FDA approves Actemra, first biologic for SSc-related interstitial lung disease
The FDA has approved subcutaneous tocilizumab to curb the rate of progressive loss of lung function among adults with systemic sclerosis-associated interstitial lung disease, according to a press release from Genentech.
IDSA updates guidance to support use of tocilizumab for COVID-19
The Infectious Diseases Society of America has backed the use of tocilizumab for COVID-19.